Pharmacy Trends
Biosimilars to Watch in 2024
Obesity Drug Spending Surges and Other U.S. Drug Trends for 2024
What Benefit Advisors Should Tell Their Clients About Discount Drug Programs
From Transparency to Gold Carding, 5 PBM State Regulation Trends from ’23
Shark vs. Pharma: Can Cuban’s Cost Plus Drugs Make a Real Impact on Medication Prices?
Appeals Court Decision Favoring PCMA Leaves Questions for ERISA Plans
10 Fast Facts About the Pharmacy Benefits Industry
Protecting Your Clients Against Off-Label Ozempic
Biosimilars, GLP-1s, and Stop-loss: Topics Benefit Advisors Need to Consider in Q3 2023
Enjoy our latest blogs, white papers and news by signing up for our newsletter today!